国家药监局受理映恩生物DB-1303/BNT323治疗HER2阳性乳腺癌的生物制品许可申请

美股速递04-09

映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1123067387?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-09 18:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123067387","market":"us","top_or_hot":-1,"title":"国家药监局受理映恩生物DB-1303/BNT323治疗HER2阳性乳腺癌的生物制品许可申请","media":"美股速递","content":"<p>映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国家药监局受理映恩生物DB-1303/BNT323治疗HER2阳性乳腺癌的生物制品许可申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国家药监局受理映恩生物DB-1303/BNT323治疗HER2阳性乳腺癌的生物制品许可申请\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-09 18:51 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","start_time":0,"source_url":"","article_id":"1123067387","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123067387","pubTimestamp":1775731872,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","09606":"映恩生物-B","BK1161":"生物科技","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元"},"translate_title":"The State Food and Drug Administration accepts the application for biological product license of Yingen Biologics DB-1303/BNT323 for the treatment of HER2-positive breast cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123067387","isCrawlerRequest":true}